Sinopharm Keeps Share Capital Unchanged and Public Float Intact in May 2026

Bulletin Express06-04

Sinopharm Group Co. Ltd filed its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, confirming that no share capital movements occurred during May 2026.

• Authorised/registered share capital held steady at 3.12 billion ordinary shares with a par value of RMB 1.00 each, comprising 1.34 billion H shares and 1.78 billion domestic shares.

• Issued share capital also remained unchanged: 1.34 billion H shares and 1.78 billion domestic shares, totalling 3.12 billion shares. The company reported zero treasury shares and no share repurchases or cancellations.

• Sinopharm affirmed compliance with Main Board Rule 13.32D, maintaining the required minimum public float threshold of 25 % for its H shares.

• No share options, warrants, convertible securities, or other agreements that could dilute existing share capital were outstanding or exercised during the month.

The monthly return was signed by Company Secretary Wu Yijian. Sinopharm’s stable capital structure and adherence to listing rules underscore its disciplined capital management over the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115650203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115650203","market":"hk","top_or_hot":-1,"title":"Sinopharm Keeps Share Capital Unchanged and Public Float Intact in May 2026","media":"Bulletin Express","content":"<p>Sinopharm Group Co. Ltd filed its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, confirming that no share capital movements occurred during May 2026.</p>\n<p>• Authorised/registered share capital held steady at 3.12 billion ordinary shares with a par value of RMB 1.00 each, comprising 1.34 billion H shares and 1.78 billion domestic shares.</p>\n<p>• Issued share capital also remained unchanged: 1.34 billion H shares and 1.78 billion domestic shares, totalling 3.12 billion shares. The company reported zero treasury shares and no share repurchases or cancellations.</p>\n<p>• Sinopharm affirmed compliance with Main Board Rule 13.32D, maintaining the required minimum public float threshold of 25 % for its H shares.</p>\n<p>• No share options, warrants, convertible securities, or other agreements that could dilute existing share capital were outstanding or exercised during the month.</p>\n<p>The monthly return was signed by Company Secretary Wu Yijian. Sinopharm’s stable capital structure and adherence to listing rules underscore its disciplined capital management over the reporting period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Keeps Share Capital Unchanged and Public Float Intact in May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Keeps Share Capital Unchanged and Public Float Intact in May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinopharm Group Co. Ltd filed its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, confirming that no share capital movements occurred during May 2026.</p>\n<p>• Authorised/registered share capital held steady at 3.12 billion ordinary shares with a par value of RMB 1.00 each, comprising 1.34 billion H shares and 1.78 billion domestic shares.</p>\n<p>• Issued share capital also remained unchanged: 1.34 billion H shares and 1.78 billion domestic shares, totalling 3.12 billion shares. The company reported zero treasury shares and no share repurchases or cancellations.</p>\n<p>• Sinopharm affirmed compliance with Main Board Rule 13.32D, maintaining the required minimum public float threshold of 25 % for its H shares.</p>\n<p>• No share options, warrants, convertible securities, or other agreements that could dilute existing share capital were outstanding or exercised during the month.</p>\n<p>The monthly return was signed by Company Secretary Wu Yijian. Sinopharm’s stable capital structure and adherence to listing rules underscore its disciplined capital management over the reporting period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"","article_id":"1115650203","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115650203","pubTimestamp":1780562873,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinopharm Group Co. Ltd filed its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, confirming that no share capital movements occurred during May 2026. • Authorised/registered share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药控股2026年5月股本不变公众持股量不变","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group Co. Ltd filed its monthly return to Hong Kong Exchanges and Clearing on 4 June 2026, confirming that no share capital movements occurred during May 2026.\n• Authorised/registered share capital held steady at 3.12 billion ordinary shares with a par value of RMB 1.00 each, comprising 1.34 billion H shares and 1.78 billion domestic shares.\n• Issued share capital also remained unchanged: 1.34 billion H shares and 1.78 billion domestic shares, totalling 3.12 billion shares. The company reported zero treasury shares and no share repurchases or cancellations.\n• Sinopharm affirmed compliance with Main Board Rule 13.32D, maintaining the required minimum public float threshold of 25 % for its H shares.\n• No share options, warrants, convertible securities, or other agreements that could dilute existing share capital were outstanding or exercised during the month.\nThe monthly return was signed by Company Secretary Wu Yijian. Sinopharm’s stable capital structure and adherence to listing rules underscore its disciplined capital management over the reporting period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115650203","isCrawlerRequest":true}